TLSA Key Statistics, Chart & Performance
The current stock price of TLSA is 1.68 USD. In the past month the price increased by 15.07%. In the past year, price increased by 127.06%.
TLSA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to TLSA. When comparing the yearly performance of all stocks, TLSA is one of the better performing stocks in the market, outperforming 93.35% of all stocks.
TLSA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TLSA Forecast & Estimates
7 analysts have analysed TLSA and the average price target is 8.16 USD. This implies a price increase of 385.71% is expected in the next year compared to the current price of 1.68.
TLSA Ownership
TLSA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About TLSA
Company Profile
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).
Company Info
TIZIANA LIFE SCIENCES LTD
3rd Floor, 11-12 St. James's Square
London SW1Y 4LB GB
CEO: Kunwar Shailubhai
Employees: 8
Phone: 442074952379
TIZIANA LIFE SCIENCES LTD / TLSA FAQ
What does TLSA do?
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).
Can you provide the latest stock price for TIZIANA LIFE SCIENCES LTD?
The current stock price of TLSA is 1.68 USD. The price increased by 15.86% in the last trading session.
Does TLSA stock pay dividends?
TLSA does not pay a dividend.
What is the ChartMill rating of TIZIANA LIFE SCIENCES LTD stock?
TLSA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the sector and industry classification for TIZIANA LIFE SCIENCES LTD?
TIZIANA LIFE SCIENCES LTD (TLSA) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of TLSA stock?
TIZIANA LIFE SCIENCES LTD (TLSA) has a market capitalization of 199.62M USD. This makes TLSA a Micro Cap stock.